Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer.

MLA

Chang, Gee-Chen, et al. “Real-World Osimertinib Pretreatment Experience in Patients with Epidermal Growth Factor Receptor T790M Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer.” PLoS ONE, vol. 19, no. 5, May 2024, pp. 1–16. EBSCOhost, https://doi.org/10.1371/journal.pone.0303046.

APA

Chang, G.-C., Shih, J.-Y., Yu, C.-J., Chao, H.-S., Yang, C.-T., Lin, C.-C., Hung, J.-Y., Hsiao, S.-Y., Wang, C.-C., Chian, C.-F., Hsia, T.-C., & Chen, Y.-M. (2024). Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer. PLoS ONE, 19(5), 1–16. https://doi.org/10.1371/journal.pone.0303046

Chicago

Chang, Gee-Chen, Jin-Yuan Shih, Chong-Jen Yu, Heng-Sheng Chao, Cheng-Ta Yang, Chien-Chung Lin, Jen-Yu Hung, et al. 2024. “Real-World Osimertinib Pretreatment Experience in Patients with Epidermal Growth Factor Receptor T790M Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer.” PLoS ONE 19 (5): 1–16. doi:10.1371/journal.pone.0303046.